Multiple sclerosis - Pathophysiology Immunology Histopathology

Pathophysiology of Multiple Sclerosis Introduction Multiple sclerosis is fundamentally an autoimmune demyelinating disease of the central nervous system (CNS). This means that the immune system mistakenly attacks myelin—the protective insulation coating around nerve fibers—leading to inflammation, demyelination (loss of myelin), and ultimately axonal damage and neuronal loss. Understanding the pathophysiology requires examining three interconnected processes: immune dysregulation, inflammation and blood-brain barrier disruption, and the consequences for myelin and axons. Immune Dysregulation: The Autoimmune Attack Multiple sclerosis involves coordinated attacks by several types of immune cells that have become autoreactive—meaning they attack the body's own tissue rather than protecting it. T Cell-Mediated Immunity The primary drivers of MS pathology are autoreactive T cells, particularly: CD8+ cytotoxic T cells directly kill oligodendrocytes (the cells that produce myelin) and may contribute to axonal damage CD4+ helper T cells (especially a subset called Th17 cells) coordinate the inflammatory response and release pro-inflammatory cytokines like TNF-α and IL-17 that amplify tissue damage These T cells recognize specific myelin antigens such as myelin basic protein (MBP) and myelin oligodendrocyte glycoprotein (MOG), treating them as foreign threats. B Cell-Mediated Immunity Autoreactive B cells contribute through two mechanisms: Antibody production: B cells produce oligoclonal immunoglobulin G (IgG) antibodies that are found in the cerebrospinal fluid of most MS patients. These antibodies bind to myelin and activate complement, driving demyelination. Antigen presentation: B cells also act as antigen-presenting cells that activate T cells, amplifying the inflammatory cascade. A Critical Research Development: Epstein-Barr Virus Recent research has identified a strong association between Epstein-Barr virus (EBV) infection and MS development. Here's what we know: EBV infection precedes MS: Nearly all MS patients have prior EBV infection (compared to 95% of the general population), and those infected with EBV are significantly more likely to develop MS Higher anti-EBNA antibody levels: Patients with MS show elevated antibodies against EBV nuclear antigen (EBNA), suggesting persistent immune activation against EBV Molecular mimicry mechanism: A particularly important finding is potential molecular mimicry between EBV's EBNA1 protein and the myelin protein GlialCAM. This means T cells activated to fight EBV may cross-react with and attack myelin B cells as the link: B cells are infected with EBV and remain latently infected. B-cell–targeting therapies (like ocrelizumab) have proven effective at reducing relapses and slowing disability progression, supporting the hypothesis that EBV-infected B cells play a key pathogenic role Blood-Brain Barrier Disruption and Inflammation The blood-brain barrier (BBB) normally acts as a selective gate, preventing most immune cells from entering the CNS. In MS, this barrier is compromised, setting off a cascade of damage. Mechanism of BBB Disruption Peripheral inflammation increases the permeability of blood vessels at the BBB, allowing T cells and other immune cells to infiltrate the CNS. Once inside, these cells encounter myelin antigens and become activated. The Inflammatory Cascade Once immune cells enter CNS lesions, they release a powerful inflammatory response: Cytokines (TNF-α, IL-17, IFN-γ) activate macrophages and further recruit immune cells Activated macrophages engulf myelin (a process called phagocytosis), directly causing demyelination Antibodies and complement bind to myelin and trigger its destruction Reactive oxygen species cause oxidative damage to both myelin and axons Lesion Formation: Demyelination and Axonal Loss The immune attack creates characteristic demyelinating lesions (also called plaques) in specific white matter regions: Optic nerve (causing vision loss) Brain stem (causing speech and swallowing problems) Basal ganglia Spinal cord (causing motor and sensory dysfunction) Periventricular regions (near the ventricles) What Happens to the Cells The damage involves two critical cellular changes: Oligodendrocyte loss: These myelin-producing cells are damaged and killed by CD8+ T cells and antibodies. Without them, myelin cannot be maintained. Demyelination: As oligodendrocytes die or are damaged, myelin thins or is completely stripped away from axons. The axons themselves become exposed and vulnerable. Axonal degeneration: Once myelin is lost, axons begin to degenerate, initially through acute injury but increasingly through cumulative long-term damage. Key Point: Axonal loss is actually the better predictor of long-term disability than demyelination itself. While demyelination can theoretically be reversed through remyelination, axonal loss is generally permanent. Remyelination Failure: Why Recovery Gets Worse Here's a critical and somewhat frustrating aspect of MS pathophysiology: the brain's repair mechanisms fail over time. In early MS, oligodendrocyte precursor cells (OPCs) can differentiate into new oligodendrocytes and remyelinate damaged axons. However, with repeated inflammatory attacks: OPCs become exhausted and fail to differentiate efficiently Chronic inflammation inhibits remyelination processes Permanent scar-like plaques form Progressive neuronal and axonal loss accumulates This explains why early relapses may be followed by nearly complete recovery, while later relapses leave lasting deficits. Role of Microglia in MS Lesions Microglia are brain-resident immune cells that take on different functional states depending on the inflammatory environment. In MS, they display remarkable complexity: Pro-inflammatory microglia contribute to lesion formation and tissue damage Anti-inflammatory microglia participate in repair and remyelination This dual role suggests that simply suppressing all microglial activation may not be ideal—the goal should be to promote reparative rather than destructive microglial responses. This remains an active area of research. Emerging Insights: Heterogeneous Auto-Antibody Responses Not all demyelinating diseases are the same, and recent research has clarified important disease subtypes based on auto-antibody profiles: Anti-Aquaporin-4 (AQP4) Antibodies Define neuromyelitis optica spectrum disorder (NMOSD) Previously considered a variant of MS but now recognized as a distinct disease Target aquaporin-4 water channels on astrocytes Associated with severe optic nerve and spinal cord involvement Anti-Myelin Oligodendrocyte Glycoprotein (MOG) Antibodies Associated with MOG-IgG disease, overlapping with certain MS variants Represent a distinct demyelinating phenotype Often associated with optic neuritis and acute disseminated encephalomyelitis Anti-Neurofascin Antibodies Less common than the above but increasingly recognized Target neurofascin at the nodes of Ranvier (sites critical for nerve impulse conduction) Associated with chronic progressive MS and combined CNS-peripheral demyelination May explain peripheral nervous system involvement in some patients Clinical Significance: Identifying which auto-antibodies a patient has is increasingly important because it may predict disease course and response to specific therapies. <extrainfo> Vitamin D and Immune Regulation Vitamin D plays an immunomodulatory role in MS pathophysiology: Promotes tolerogenic dendritic cells: These dendritic cells help suppress rather than activate T cell responses Reduces Th1/Th17 responses: Vitamin D dampens the pro-inflammatory T cell subsets most involved in MS pathology Geographic variation: The association between vitamin D deficiency and MS risk may partially explain the higher prevalence of MS in northern latitudes with less sun exposure </extrainfo> <extrainfo> Biomarkers of Pathological Processes Two emerging biomarkers reflect the pathological processes occurring in MS: Iron Accumulation Iron deposits accumulate within lesions and surrounding tissue Serves as a sensitive marker of ongoing inflammation Can be detected by specialized MRI sequences May contribute to oxidative stress and neurodegeneration Neurofilament Light Chain Elevated levels in cerebrospinal fluid reflect axonal injury and degeneration Correlates with disease activity Shows promise as a biomarker for monitoring disease progression and treatment response </extrainfo>